Grifols signs $3.4bn loans for Talecris acquisition
Spanish healthcare company Grifols has signed the loan agreements backing its takeover of US biotherapy and biotechnology company Talecris, after an oversubscribed syndication phase. High yield bonds worth $1.1bn will be issued in the next few weeks.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
